Jupiter Neurosciences, Inc. (JUNS) Stock Score, Valuation & Financial Research

Jupiter Neurosciences, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 19/100.

Quick answer for JUNS

Jupiter Neurosciences, Inc. currently has a Wall Street Score of 19/100. The stored market price is $2.86. Its financial score is 6/100. Its valuation score is 0/100. The latest WSS change is +4.2 points. These figures are a research snapshot, not a buy or sell recommendation.

What Jupiter Neurosciences, Inc. does

Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in clinical-stage research and development. Its primary focus is on advancing a resveratrol-based platform product, with the main objective of addressing neuro-inflammation. The company's pipeline includes several drug candidates: JNS101 is undergoing Phase II trials for Friedreich's Ataxia, a rare neurological disorder that damages the nervous system and causes mobility issues. Also in Phase II, JNS102 is being developed for mucopolysaccharidosis Type I, JNS107 for MELAS Syndrome, and JNS108 for mild cognitive impairment and early Alzheimer's disease. Furthermore, the company is progressing JNS109 for amyotrophic lateral sclerosis, JNS110 for traumatic brain injury and concussion, and JNS120 as a treatment for COVID-19. Founded in 2016, the company, formerly known as Jupiter Orphan Therapeutics, Inc., adopted its current na

JUNS financial snapshot

Wall Street Score:: 19/100
Current price:: $2.86
Market capitalization:: $1.4M
Revenue:: $65K
Net income:: $-9.2M
Free cash flow:: $-5.4M
Cash:: $1.5M
Total debt:: $1.7M
EPS:: -19.33
Financial score:: 6/100
Valuation score:: 0/100

What stands out

Reported year-over-year revenue growth is +2.0%.
Free cash flow is $-5.4M, showing cash burn in the current stored period.
The balance sheet shows $1.5M of cash versus $1.7M of total debt, so leverage deserves attention.
The latest Wall Street Score change is +4.2 points: JUNS increased 4.2 points because Asset improved by 41.1 points.
The current research record carries a severe debt stress warning, which should be reviewed alongside the score.

Questions worth answering for JUNS

These questions are derived from the company's current stored financial and score data so the page adds company-specific research context instead of treating the headline score as a stand-alone conclusion.

Can JUNS maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
How long can JUNS fund negative free cash flow using its current cash position before it may need more debt or new shares?
Does JUNS's balance between cash and debt leave enough flexibility if business conditions weaken?
What specifically needs to improve for JUNS to reach sustainable profitability?
What future growth or profitability would be needed to justify JUNS's current valuation?

What the numbers mean

Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.

The financial score is 6/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-09-19.

Research-input completeness: 82% of the scoring inputs required for this public page are currently available.

How to research JUNS

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.